Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Oogenesis02:07

Oogenesis

63.9K
In human women, oogenesis produces one mature egg cell or ovum for every precursor cell that enters meiosis. This process differs in two unique ways from the equivalent procedure of spermatogenesis in males. First, meiotic divisions during oogenesis are asymmetric, meaning that a large oocyte (containing most of the cytoplasm) and minor polar body are produced as a result of meiosis I, and again following meiosis II. Since only oocytes will go on to form embryos if fertilized, this unequal...
63.9K
Infertility in Females01:28

Infertility in Females

360
Female infertility is defined as the inability to conceive after a year of regular, unprotected intercourse and affects about 10–15% of couples worldwide. The primary cause of female infertility is ovulatory disorders, which hinder the release of eggs. These disorders can be classified as hypothalamic amenorrhea, polycystic ovarian syndrome (PCOS), premature ovarian failure, and hyperprolactinemic anovulation disorders.
Endometriosis, a condition characterized by abnormal growth of...
360
Menopause01:28

Menopause

218
Menopause, a natural biological process marking the end of a woman's fertility, typically occurs between the fifth and sixth decade of life. This phase is characterized by the exhaustion of the ovarian follicle pool, leading to less responsive ovaries despite the high levels of Follicle Stimulating Hormone (FSH) and Luteinizing Hormone (LH). The consequential decrease in estrogen production results in symptoms like hot flashes, heavy sweating, headaches, hair loss, muscle pains, vaginal...
218
Ovarian Cycle01:27

Ovarian Cycle

1.5K
The menstrual cycle includes a critical component known as the ovarian cycle, which undergoes two main phases each month—the follicular phase and the luteal phase. The follicular phase is variable and averaging around 14 days. Ovulation, triggered by a surge in luteinizing hormone (LH), marks the transition between the two phases. The second phase, the luteal phase, is relatively consistent, lasting approximately 14 days, and is marked by the activity of the corpus luteum. While a cycle...
1.5K
Hormonal Control of the Ovarian Cycle01:30

Hormonal Control of the Ovarian Cycle

607
The ovarian cycle is meticulously regulated by the hypothalamic-pituitary-gonadal axis. This cycle orchestrates the release of a mature oocyte, essential for reproduction.
Before puberty, the hypothalamus releases GnRH in a low frequency, low amplitude pulsatile manner. This along with the immature hypothalamic-pituitary-gonadal axis activity, results in low estrogen levels and the absence of a fully functional ovarian cycle.  At puberty, GnRH secretion increases in both frequency and...
607
Ovaries01:26

Ovaries

1.1K
The ovaries are roughly the size of almonds and measure approximately 2 to 3 centimeters in length. These paired structures are situated within the pelvic region and are anchored by the mesovarium—a peritoneal extension that also connects them to the wider structure of the broad ligament. The support system extends to the suspensory ligament, housing blood and lymphatic vessels. In addition, the ovarian ligament tethers the ovaries to the uterus.
On the ovarian surface, a layer of...
1.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

United States Menopausal Hormone Therapy Usage Trends: An Observational Study.

Mayo Clinic proceedings·2026
Same author

Reply: Evaluation of the accuracy and readability of large language model responses on menopause and hormone therapy.

Menopause (New York, N.Y.)·2026
Same author

Menopause symptoms and treatment in sexual minority women.

Menopause (New York, N.Y.)·2026
Same author

PAMD-Ch17, a Polymeric Analog of Plerixafor, Induces Mitochondrial Dysfunction in T-ALL Cells Independent of CXCR4.

Molecular cancer therapeutics·2026
Same author

Accuracy of Patient Self-Reported Menopause Stage: A Cross-Sectional Study.

Mayo Clinic proceedings·2026
Same author

Long-term amyloid PET and MRI outcomes in a menopausal hormone therapy trial.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026

Related Experiment Video

Updated: Aug 6, 2025

Z-Scores for Assessing Ovarian Reserve in Young Patients Undergoing Fertility Preservation
05:42

Z-Scores for Assessing Ovarian Reserve in Young Patients Undergoing Fertility Preservation

Published on: October 25, 2024

1.2K

Premature Ovarian Insufficiency.

Ekta Kapoor1,2,3,4

  • 1Center for Women's Health, Mayo Clinic, Rochester, MN, USA.

Current Opinion in Endocrine and Metabolic Research
|March 20, 2023
PubMed
Summary
This summary is machine-generated.

Premature ovarian insufficiency, or premature menopause before 40, increases health risks due to early estrogen loss. Hormone replacement therapy until natural menopause age is underused but crucial for managing symptoms and long-term health.

More Related Videos

Fertility Preservation in Patients with Severe Ovarian Dysfunction
12:03

Fertility Preservation in Patients with Severe Ovarian Dysfunction

Published on: March 25, 2021

4.7K
OP-IVM: Combining In vitro Maturation after Oocyte Retrieval with Gynecological Surgery
05:31

OP-IVM: Combining In vitro Maturation after Oocyte Retrieval with Gynecological Surgery

Published on: May 9, 2021

4.1K

Related Experiment Videos

Last Updated: Aug 6, 2025

Z-Scores for Assessing Ovarian Reserve in Young Patients Undergoing Fertility Preservation
05:42

Z-Scores for Assessing Ovarian Reserve in Young Patients Undergoing Fertility Preservation

Published on: October 25, 2024

1.2K
Fertility Preservation in Patients with Severe Ovarian Dysfunction
12:03

Fertility Preservation in Patients with Severe Ovarian Dysfunction

Published on: March 25, 2021

4.7K
OP-IVM: Combining In vitro Maturation after Oocyte Retrieval with Gynecological Surgery
05:31

OP-IVM: Combining In vitro Maturation after Oocyte Retrieval with Gynecological Surgery

Published on: May 9, 2021

4.1K

Area of Science:

  • Reproductive Endocrinology
  • Women's Health
  • Hormone Therapy

Background:

  • Natural menopause occurs between 46-55 years.
  • Premature ovarian insufficiency (POI) is ovarian function loss before age 40.
  • POI leads to early estrogen loss, causing symptoms and long-term health risks, including increased mortality.

Purpose of the Study:

  • To highlight the underutilization of hormone replacement therapy (HRT) in premature menopause.
  • To educate patients and providers on the impact of POI.
  • To emphasize the necessity of appropriate POI management.

Main Methods:

  • Review of current literature on POI and HRT.
  • Analysis of risks and benefits of HRT in women with POI.
  • Discussion of barriers to HRT use in this population.

Main Results:

  • Estrogen deprivation from POI causes significant short- and long-term health issues.
  • HRT is effective in managing POI symptoms and mitigating long-term health risks.
  • HRT is underused in POI due to misapplication of risks observed in women undergoing natural menopause.

Conclusions:

  • POI requires specific management strategies distinct from natural menopause.
  • Increased education is needed for patients and healthcare providers regarding POI.
  • Appropriate HRT use is essential for improving health outcomes in women with POI.